127 related articles for article (PubMed ID: 17230230)
1. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.
Stewart AK; Bergsagel PL; Greipp PR; Dispenzieri A; Gertz MA; Hayman SR; Kumar S; Lacy MQ; Lust JA; Russell SJ; Witzig TE; Zeldenrust SR; Dingli D; Reeder CB; Roy V; Kyle RA; Rajkumar SV; Fonseca R
Leukemia; 2007 Mar; 21(3):529-34. PubMed ID: 17230230
[TBL] [Abstract][Full Text] [Related]
2. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.
Stewart AK; Fonseca R
J Clin Oncol; 2005 Sep; 23(26):6339-44. PubMed ID: 16155017
[TBL] [Abstract][Full Text] [Related]
4. Myeloma: classification and risk assessment.
Fonseca R; Monge J
Semin Oncol; 2013 Oct; 40(5):554-66. PubMed ID: 24135400
[TBL] [Abstract][Full Text] [Related]
5. Review of molecular diagnostics in multiple myeloma.
Stewart AK; Fonseca R
Expert Rev Mol Diagn; 2007 Jul; 7(4):453-9. PubMed ID: 17620051
[TBL] [Abstract][Full Text] [Related]
6. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
[TBL] [Abstract][Full Text] [Related]
7. Risk stratification in the era of novel therapies.
San-Miguel J; Mateos MV; Gutierrez NC
Cancer J; 2009; 15(6):457-64. PubMed ID: 20010164
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of cytogenetic aberrations in patients with multiple myeloma or monoclonal gammopathy of unknown significance.
Schilling G; Dierlamm J; Hossfeld DK
Hematol Oncol; 2005; 23(3-4):102-7. PubMed ID: 16342296
[TBL] [Abstract][Full Text] [Related]
9. Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation.
Chang H; Qi XY; Samiee S; Yi QL; Chen C; Trudel S; Mikhael J; Reece D; Stewart AK
Bone Marrow Transplant; 2005 Nov; 36(9):793-6. PubMed ID: 16113669
[TBL] [Abstract][Full Text] [Related]
10. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
[TBL] [Abstract][Full Text] [Related]
11. Genomics in multiple myeloma: biology and clinical implications.
Chng WJ; Fonseca R
Pharmacogenomics; 2005 Sep; 6(6):563-73. PubMed ID: 16142997
[TBL] [Abstract][Full Text] [Related]
12. [Close correlations between CD20 expression, a small mature plasma cell morphology and t(11 ; 14) in multiple myeloma].
Matsuda I; Mori Y; Nakagawa Y; Sawanobori M; Uemura N; Suzuki K
Rinsho Ketsueki; 2005 Dec; 46(12):1293-7. PubMed ID: 16447802
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of novel therapeutic targets for multiple myeloma.
Hideshima T; Chauhan D; Richardson P; Anderson KC
J Clin Oncol; 2005 Sep; 23(26):6345-50. PubMed ID: 16155018
[TBL] [Abstract][Full Text] [Related]
14. An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy.
Boccadoro M; Tarella C; Palumbo A; Argentino C; Triolo S; Dominietto A; Callea V; Lauta VM; Molica S; Musto P; Marmont F; Gianni AM; Pileri A
Haematologica; 1999 Oct; 84(10):905-10. PubMed ID: 10509038
[TBL] [Abstract][Full Text] [Related]
15. [Molecular genetic methods for the prognostic criteria in multiple myeloma].
Mikala G; Jákó J; Vályi-Nagy I
Orv Hetil; 2005 Aug; 146(32):1673-82. PubMed ID: 16149245
[TBL] [Abstract][Full Text] [Related]
16. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
[TBL] [Abstract][Full Text] [Related]
17. Fundamentals in the management of multiple myeloma.
Fadilah SA
Med J Malaysia; 2010 Sep; 65(3):231-9. PubMed ID: 21939177
[TBL] [Abstract][Full Text] [Related]
18. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients.
Carrasco DR; Tonon G; Huang Y; Zhang Y; Sinha R; Feng B; Stewart JP; Zhan F; Khatry D; Protopopova M; Protopopov A; Sukhdeo K; Hanamura I; Stephens O; Barlogie B; Anderson KC; Chin L; Shaughnessy JD; Brennan C; Depinho RA
Cancer Cell; 2006 Apr; 9(4):313-25. PubMed ID: 16616336
[TBL] [Abstract][Full Text] [Related]
19. [Genetic tools for risk-stratification in multiple myeloma].
Braggio E; Albarracín Garramuño F
Medicina (B Aires); 2013; 73(4):369-75. PubMed ID: 23924539
[TBL] [Abstract][Full Text] [Related]
20. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.
Sawyer JR
Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
